Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 11/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25253376 | 0.90 | CACNA1B (0.48) | TRPV4PKMCACNA1BPLA2G1BATG4B | |
| SCHEMBL30490344 | 0.86 | F13A1 (0.48) | TRPV4PKMCACNA1BALDH1A1 | |
| SCHEMBL23849998 | 0.81 | TRPV4 (0.46) | TRPV4PKMALDH1A1MEN1TSHR | |
| SCHEMBL25259825 | 0.81 | ALDH1A1 (0.47) | TRPV4PKMCACNA1BALDH1A1MEN1 | |
| SCHEMBL25301193 | 0.81 | EPHX2 (0.48) | TRPV4PKMCACNA1BMEN1TSHR | |
| SCHEMBL25296539 | 0.78 | F13A1 (0.50) | CACNA1BALDH1A1 | |
| SCHEMBL23850293 | 0.75 | EPHX2 (0.47) | TRPV4PKMCACNA1BALDH1A1MEN1 | |
| SCHEMBL25371394 | 0.74 | TRPV4 (0.44) | TRPV4CACNA1BKMT2A | |
| SCHEMBL30490350 | 0.73 | MGLL (0.61) | — | |
| SCHEMBL30409323 | 0.72 | MGLL (0.43) | TRPV4PKMCACNA1BPLA2G1BATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3883936-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | TRPV4 3914/4885PKM 2355/4885CACNA1B 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.